UMR 8203 Vectorologie et Thérapeutiques anticancéreuses, CNRS, Univ. Paris-Sud, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France

​

Résumé de la présentation

​

Vectors derived from Adenovirus (Ad) were used in different preclinical studies as well as in clinical trials for the purpose of vaccination. The high seroprevalence of neutralizing antibodies (Ab) as well as the induction of strong anti-vector immunity after first administration of naïve receivers led to the use of Ad from serotypes of low prevalence or even xenotypes. Capitalizing on the knowledge of the structure of Ad capsid, epitope display constitutes an alternative vaccination approach based on genetic insertion of peptides into Ad capsid proteins. Using an ovalbumin-derived epitope (Ova 320-341 ), we previously unraveled that the efficacy of epitope display is shaped by both the site of Ova 320-341 insertion but also by pre-existing anti-Ad immunity. More recently, we examined the molecular determinants controlling the efficacy of this vaccination strategy.

Anchim A, Raddi N, Zig L, Perrieau P, Le Goffic R, Ryffel B & Benihoud K. Humoral responses elicited by adenovirus displaying epitopes are induced independently of the infection process and shaped by the TLR/MyD88 pathway. Frontiers in Immunology, 2018, 9:124 ; doi:10.3389/fimmu.2018.00124.

​

Résumé du parcours :